The DUS3L Knockout MES-OV Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the MES-OV ovarian carcinoma cell line, engineered for targeted disruption of the DUS3L gene (dual specificity phosphatase 3-like). This polyclonal model provides a heterogeneous loss-of-function platform that avoids clonal artifacts, enabling robust population-level analysis of DUS3L-dependent signaling pathways in cancer biology. The knockout is achieved via CRISPR/Cas9-mediated gene disruption, generating a mixed population of cells with varied editing outcomes, which is ideal for studying phosphatase-regulated phenotypes.
The host MES-OV cell line originates from a patient with epithelial ovarian carcinoma and is widely used as a clinically relevant model for ovarian cancer research. MES-OV cells retain molecular features of high-grade serous carcinoma, including constitutive activation of MAPK signaling, making them an appropriate background to investigate the role of DUS3L in oncogenic processes. Their adherent growth and tumorigenic properties provide a physiologically relevant context for functional studies.
DUS3L encodes a dual specificity phosphatase that dephosphorylates both phosphoserine/threonine and phosphotyrosine residues, functioning as a critical negative regulator of MAPK cascades. Under normal conditions, DUS3L is activated by upstream stimuli such as growth factors, oxidative stress, and cytokines, and it directly targets phosphorylated ERK1/2, JNK, and p38 MAP kinases. By dephosphorylating these effectors, DUS3L attenuates the activity of downstream transcription factors including c-Fos and c-Jun. The phosphatase interacts with scaffold proteins like KSR1, localizing its activity within the RAS-RAF-MEK-ERK axis and stress-activated JNK/p38 modules, thereby coordinating dephosphorylation and influencing cell cycle progression and apoptosis.
Disruption of DUS3L in MES-OV cells removes this negative regulatory node, resulting in hyperactivation of ERK1/2, JNK, and p38 MAPK signaling. In the context of ovarian cancer, sustained MAPK pathway activity drives enhanced cell proliferation, survival, and invasive behavior, underscoring the tumor-suppressive function of DUS3L. This polyclonal knockout model mimics phosphatase deficiency observed in certain aggressive tumor subtypes, enabling researchers to dissect how aberrant kinase signaling reshapes the malignant phenotype and alters expression of MAPK-responsive genes such as c-Fos. The system also permits evaluation of compensatory feedback loops within the signaling network.
This knockout product is ideally suited for a wide range of applications, including mechanistic investigations of phosphatase-dependent signal transduction, validation of candidate drug targets, and CRISPR-based functional genomic screens. Typical experimental assays include western blotting to measure phospho-ERK1/2 levels, RT-qPCR to quantify transcript levels of c-Fos and c-Jun, cell proliferation and apoptosis assays, and migration/invasion assays to assess metastatic potential. High-content phospho-signaling arrays can further characterize global pathway alterations. For further technical details or customized applications, please contact Ascent Research.
